A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease

BACKGROUND: Interleukin-1 receptor 1 (IL-1R1) inhibition is a potential strategy for treating patients with chronic obstructive pulmonary disease (COPD). MEDI8968, a fully human monoclonal antibody, binds selectively to IL-1R1, inhibiting activation by IL-1α and IL-1β. We studied the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Calverley, Peter M. A., Sethi, Sanjay, Dawson, Michelle, Ward, Christine K., Finch, Donna K., Penney, Mark, Newbold, Paul, van der Merwe, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551010/
https://www.ncbi.nlm.nih.gov/pubmed/28793896
http://dx.doi.org/10.1186/s12931-017-0633-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551010/
https://www.ncbi.nlm.nih.gov/pubmed/28793896
http://dx.doi.org/10.1186/s12931-017-0633-7

Ejemplares similares